Home About Us Research & Development Investors & Media Careers Contact Us
   
   
 
NASDAQ: CNCE
8.16
+ 0.19 (2.32%)
4:00 PM ET on Jul 22, 2014
~20 min. delay
 
     
 

Investor Relations

At Concert Pharmaceuticals, we create novel medicines that address medically important needs by applying our DCE Platform® (Deuterated Chemical Entity Platform) to compounds with well-characterized pharmacological activity.  This approach may enable drug discovery and clinical development that is more efficient and less expensive than conventional small molecule drug research and development.

The company was co-founded by Richard Aldrich, Roger Tung and Christoph Westphal, and is located in the historic town of Lexington, Massachusetts.

Press Releases

Jul 21, 2014
Jul 16, 2014

Events & Presentations

Sep 4, 2014 at 10:15 AM ET

IR Contact

Justine E. Koenigsberg
Vice President,
Corporate Communications
and Investor Relations
781.674.5284
ir@concertpharma.com

Letter to Shareholders

Shareholder Letter

[ back to top ]